ObsEva has resecured the China rights to its pregnancy drug after Yuyuan BioScience allegedly failed to hit pre-agreed milestones on time.

据称玉源生物科学未能按时达到预先商定的里程碑后，ObsEva重新获得了中国对其妊娠药的权利。

The early-stage drug, called nolasiban, is an oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in women undergoing in vitro fertilization. After ObsEva significantly shrunk its head count and pipeline last year, nolasiban is one of only two drugs still listed on the biotech’s portfolio..

称为nolasiban的早期药物是一种口服催产素受体拮抗剂，正在开发用于改善体外受精妇女的临床妊娠和活产率。在去年ObsEva显着缩小其人数和管道后，nolasiban是生物技术投资组合中仅有的两种药物之一。。

Obseva granted Yuyuan an exclusive sublicense to develop and commercialize nolasiban in China in January 2020. The agreement gave ObsEva the rights to terminate the deal with immediate effect if Yuyuan didn’t meet “certain development milestones … within certain deadlines,” the Swiss company said in a release July 13..

Obseva授予Yuyuan 2020年1月在中国开发和商业化nolasiban的独家子许可。瑞士公司在7月13日发布的一份报告中说，该协议允许ObsEva有权在Yuyuan未达到“某些发展里程碑……在特定期限内”时立即终止交易。。

“Under these terms, on July 12, 2023, ObsEva decided to notify Yuyuan of its breach to comply with certain set milestones and the license rights on nolasiban previously granted to Yuyuan forthwith reverted to ObsEva,” the company explained.

“根据这些条款，2023年7月12日，ObsEva决定通知Yuyuan违反规定的里程碑，先前授予Yuyuan的nolasiban许可权立即恢复为ObsEva，”公司解释说。

Things had seemed to be on track as recently as October, when Yuyan secured approval from Chinese authorities for a phase 1 trial to evaluate nolasiban in healthy adult females. At the time, ObsEva said the China trial would “provide critical observations that will inform nolasiban’s future development in the U.S.

最近10月，当Yuyan获得中国当局批准进行第一阶段试验以评估健康成年女性中的nolasiban时，事情似乎正在正常进行。当时，ObsEva表示，中国的审判将“提供批判性的意见，为诺拉西班在美国的未来发展提供信息。

and abroad.”.

国外。”。

Ending the partnership means ObsEva loses out on any chance to receive the over $130 million in combined development and sales milestones set out in the original agreement.

结束合作意味着ObsEva有机会在原始协议中规定的综合开发和销售里程碑中获得超过1.3亿美元。

The company had previously tested nolasiban in a phase 3 trial to see whether it increased the rate of clinical pregnancy 10 weeks after embryo transfer. This year, the biotech set out plans for a phase 1 multiple dose study in preparation for a phase 2 trial in early 2024.

该公司之前曾在3期试验中测试了nolasiban，以观察其是否在胚胎移植后10周增加了临床妊娠率。今年，生物技术公司制定了第一阶段多剂量研究计划，为2024年初的第二阶段试验做准备。

ObsEva’s only other remaining asset is preterm labor treatment ebopiprant, for which Xoma is entitled to royalties and milestone payments. ObsEva had hoped that selling off the license for ebopiprant to Xoma in November would be enough to halt debt proceedings in court and perhaps prevent the Swiss biotech from dropping off the Nasdaq, but, by February, the company had to demolish its U.S.

ObsEva唯一剩余的资产是早产治疗ebopiprant，Xoma有权获得版税和里程碑付款。ObsEva希望在11月份将ebopiprant的许可证出售给Xoma足以阻止法庭上的债务诉讼，也许会阻止瑞士生物技术公司从纳斯达克退市，但到2月份，该公司不得不拆除其美国。

C-suite in order to claw back further savings..

C套件，以节省更多费用。。